Psychedelics, also called hallucinogens, are compounds that profoundly alter consciousness, perception, mood, and cognition. The term comes from Greek, meaning “mind manifesting.” These drugs mainly act on serotonin receptors in the brain. They fall into three chemical groups: tryptamines (psilocybin, DMT), phenethylamines (mescaline), and ergolines (LSD). Some come from plants or mushrooms, while others are lab-made. Importantly, researchers now study them for mental health conditions like depression and PTSD.

Short-Term Effects and Risks

Psychedelics produce a range of effects, from euphoria and vivid visual changes to intense emotional shifts. Users may feel deeply connected or, conversely, experience confusion, anxiety, or panic. Physical effects include nausea, headache, and elevated heart rate. While serious risks are lower in controlled settings, challenging experiences (previously called “bad trips”) can occur. Persistent distress lasting days or weeks is rare but possible. Importantly, these drugs show low physiological dependence and abuse potential due to rapid tolerance.

Therapeutic Research and Legal Status

Recent clinical trials show psilocybin can produce lasting improvements in depression, anxiety, and substance use disorders. For instance, studies report remission rates of 25-57% for treatment-resistant depression. However, experts caution that the evidence remains early-stage and not yet sufficient for routine clinical use. Most psychedelics remain Schedule I substances in the US and Class A drugs in the UK, legal only in tightly controlled research settings. Therefore, further high-quality research is essential to confirm safety and efficacy.